TABLE 1.

Alternative splicing signatures associated with overall survival in patients with pancreatic cancer.

AS type	Formula	HR (95% CI)	AUC
AA	(MTMR10|29790|AA ×−71.23) + (OXNAD1|63641|AA ×−47.12) + (IPO8|20939|AA ×−28.79) + (RUFY2|11939|AA × 3.86) + (TRAPPC8|45017|AA ×−40.07) + (DLG4|38849|AA ×−6.22) + (DNAJC21|71747|AA × 8.29) + (POLM|79444|AA × 3.64) + (GMPPA|95766|AA ×−4.06) + (RNF121|17460|AA ×−5.29) + (GUCD1|61411|AA ×−7.21) + (PRRG2|50978|AA ×−8.78)	2.014 (1.318–3.076)	0.800
AD	(NUDT9|69869|AD ×−14.2) + (PPP1R7|58334|AD × 13.47) + (MFSD11|43685|AD ×−5.35) + (MEN1|16702|AD ×−17.4) + (FAM46A|76832|AD ×−4.54) + (PUM1|1443|AD ×−3.95) + (TXNDC17|38768|AD × 15) + (CLTCL1|61046|AD × 2.8) + (NRD1|2988|AD × 34.24) + (PDPN|713|AD ×−7.46) + (SPAG8|86314|AD ×−1.63) + + (ZFAND1|84310|AD ×−6.12) + (CENPW|77443|AD ×−5.31)	2.794 (1.809–4.316)	0.823
AP	(SLC20A2|83730|AP × 5.86) + (KANK1|85709|AP × 2.04) + (CLDN18|66949|AP × 6.57) + (TJP2|86531|AP × 2.38) + (RNF14|73838|AP ×−23.94) + (GRB7|40692|AP ×−6.58) + (ADPRHL1|26374|AP ×−2.88) + (MLLT3|85978|AP × 3.48) + (APTX|86073|AP × 2.87) + (TMEM243|80314|AP × 1.72) + (NFYB|24094|AP × 3.61)	0.982 (0.645–1.494)	0.905
AT	(DTNA|45096|AT × 7.65) + (ZNF695|10501|AT ×−0.71) + (ACYP2|53566|AT ×−4.88) + (KCNIP1|74491|AT ×−2.44) + (ZNF208|48800|AT × 5.4) + (DEPDC5|61896|AT ×−10.18) + (ZNF230|50262|AT ×−9.89) + (FHAD1|749|AT × 2.49) + (RNF32|82452|AT × 8.22) + (AADAC|67304|AT ×−18.98) + (CFLAR|56792|AT ×−7.79)	1.779 (1.170–2.705)	0.829
ES	(MTMR10|29791|ES ×−27.62) + (KIAA0922|70873|ES ×−4.61) + (INTS6|25947|ES ×−23.67) + (FDXR|43316|ES ×−64.23) + (ACHE|81032|ES ×−5.77) + (DDX19B|37348|ES ×−10.8) + (ELP3|83203|ES ×−6.91) + (HEXA|31549|ES ×−2.39) + (TUBD1|42826|ES ×−5.85) + (TMEM126B|18121|ES × 10.55) + (LRRC28|32678|ES ×−8.03) + (PLEKHB2|55371|ES ×−7.55) + (INTS7|9724|ES ×−12.46) + (KDM5C|89207|ES ×−5.7) + (PUM2|52774|ES × 6.56)	2.185 (1.432–3.336)	0.887
ME	(PTK2|98071|ME ×−2.64) + (C4orf29|70560|ME ×−2.5) + (P4HA1|12122|ME ×−4.8) + (DLG3|89383|ME × 43.86)	1.468 (0.965–2.233)	0.681
RI	(DLK1|93561|RI ×−20.93) + (ZBTB47|64310|RI ×−16.87) + (CD14|73687|RI ×−10.56) + (SIX5|50518|RI ×−13.35) + (MFSD11|43684|RI ×−6.28) + (C12orf73|24078|RI × 1.16) + (KRT15|40913|RI ×−1.92) + (B3GALNT1|67498|RI ×−18.48) + (POLR3H|62436|RI ×−5.12) + (EXOSC9|70501|RI ×−1.84) + (MPZ|8658|RI ×−8.1) + (ZNF169|86929|RI ×−6.98)	1.809 (1.189–2.752)	0.847
ALL	(MTMR10|29790|AA ×−68.75) + (SLC20A2|83730|AP × 3.51) + (NUDT9|69869|AD ×−11.11) + (FDXR|43316|ES ×−44.84) + (DLK1|93561|RI ×−27.79) + (OXNAD1|63641|AA ×−40.37) + (KANK1|85709|AP × 2.21) + (NFKB2|12948|AA ×−8.6) + (DTNA|45096|AT × 8.56) + (ACHE|81032|ES ×−10.5) + (ZBTB47|64310|RI ×−33.9) + (ELP3|83203|ES ×−16.26)	1.980 (1.293–3.033)	0.943

AS, alternative splicing; HR, hazard ratio; AUC, area under curve; AA, alternate acceptor; AD, alternate donor sites; AP, alternate promoters; AT, alternate terminators; ES, exon skips, ME, mutually exclusive exons; RI, retained introns; ALL, all types.